Neoadjuvant survivin-targeted immunotherapy maveropepimut-S (MVP-S) to increase Th1 immune response in Ki67-high hormone receptor-positive (HR+) early-stage breast cancer (ESBC).
Document Type
Presentation
Publication Date
12-7-2022
Keywords
oregon; chiles
Area of Special Interest
Cancer
Area of Special Interest
Women & Children
Specialty/Research Institute
Oncology
Specialty/Research Institute
Earle A. Chiles Research Institute
Comments
Presented at the SABCS Annual Meeting; 2022 December 7; San Antonio, TX.